Market Trends of Chemotherapy-Induced Neutropenia (CIN) Treatment Industry
Granulocyte Colony-Stimulating Factor Therapy Segment is Expected to Witness Significant Growth Over the Forecast Period
Granulocyte colony-stimulating factor therapy (G-CSF) is the most common treatment for cancer-related neutropenia. It is among the most widely prescribed supportive care medications for breast and lymphoma malignancies. The granulocyte colony-stimulating factor therapy segment is anticipated to grow with the advancing research and recent developments by the market players.
Research studies have highlighted the efficacy of the G-CSF therapy, which is anticipated to increase the adoption of the G-CSF therapies for the effective management of cancer-related neutropenia. For instance, a study published in the journal Biology in October 2021 demonstrated that filgrastim and its biosimilars demonstrated to prevent febrile neutropenia in cancer patients. Such studies are expected to increase the demand for G-CSF therapy for treating cancer-related neutropenia, which in turn is expected to boost the segment's growth.
Furthermore, the increasing company focus on developing granulocyte colony-stimulating factor therapy drugs for treating chemotherapy-induced neutropenia in cancer patients through various business strategies such as product launches, agreements, mergers, and collaboration also contribute to the segment growth over the forecast period. For instance, in October 2022, Spectrum Pharmaceuticals received FDA approval for its Rolvedon (eflapegrastim-xnst) to manage non-myeloid malignancies. The drug is a recombinant human granulocyte-colony stimulating factor (GCSF) and is the first novel long-acting GCSF (LA-GCSF) product approved in over 20 years. Furthermore, in February 2022, Lupin signed a license, supply, and technology-sharing agreement with Axantia Holding. Under this agreement, Axantia will be responsible for registering, distributing, and marketing biosimilar Pegfilgrastim drug products in certain territories, including Saudi Arabia, certain GCC countries, Jordan, Lebanon, Iraq, Sudan, Libya, and Algeria.
Therefore, with the increasing adoption of granulocyte colony-stimulating factor therapy (G-CSF) as the primary treatment and increasing company focus on developing effective therapies for treatment against neutropenia in cancer patients, the studied segment is expected to grow over the forecast period.
North America is Expected to Witness Significant Growth Over the Forecast Period
North America is anticipated to have a significant market share owing to factors such as the increasing prevalence of cancer, rising demand for disease-specific treatment, high healthcare spending, well-defined infrastructure, and the presence of market players in the region. The rising prevalence of cancer cases in the region is the key driving factor for the market's growth over the forecast period, as chemotherapy is the major cancer treatment, which often further leads to neutropenia. Research studies have highlighted the burden of cancer-related neutropenia in the region, which is expected to boost the demand for chemotherapy-induced neutropenia (CIN) treatment. For instance, according to an article published in the journal Oncologist in August 2022, it is observed that the in-hospital mortality rates for neutropenia/F.N. range from 0.4% to 3.0% for pediatric patients with cancer, 2.6% to 7.0% for adults with solid tumors, and 7.4% for adults with hematologic malignancies. Such instances indicate the need for chemotherapy, which in turn is expected to propel the market growth in the region.
The United States is expected to witness considerable growth among other countries in the North American region. The increasing company focus on developing advanced and efficient therapies for treating chemotherapy-induced neutropenia and increasing drug approvals in the country are the major contributors to the market growth in the country. For instance, in April 2022, Spectrum Pharmaceutical received acceptance for its resubmitted Biologics License Application (BLA) for eflapegrastim by the U.S. FDA for treating chemotherapy-induced neutropenia. Furthermore, in June 2021, BeyondSpring Inc. filed a new drug application, along with a priority review, for its plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN), to the United States Food and Drug Administration.
Thus, the increasing prevalence of cancer, the use of chemotherapy as treatment, and increasing research and development activities in the region are expected to propel market growth over the forecast period.
